GoldenGolden
Advanced Search
Versant Ventures

Versant Ventures

A venture capital and private equity firm investing companies focused on the discovery and development of novel therapeutics, medical devices and diagnostics.

Versant Ventures is a venture capital and private equity firm investing in biopharmaceuticals, biotechnology platforms, specialty pharmaceuticals, healthcare services, and healthcare information technology companies. The firm is headquartered in Menlo Park, California and was founded in 1999 by Barbara Lubash, Brian Atwood, Donald B. Milder, Rebecca Robertson, Samuel Colella, and William Link. Versant Ventures makes debt, early stage, late stage, and private equity investments. According to the firms website they have $3.2 billion under management, 34 initial public offerings, and 42 mergers & acquisitions.

Notable exits made by Versant Ventures include: Adverum Biotechnologies, Akero, BlueRock Therapeutics, Ceterix Orthopaedics, CymaBay Therapeutics, Forsight Vision4, Gritstone Oncology, NeuWave Medical, Okairos, Twelve, and WaveTec Vision.

Timeline

Associated investment funds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
FinSMEs
August 2, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Kyle LaHucik
June 17, 2021
FierceBiotech
LENZ Therapeutics re-emerged Thursday after saying goodbye to the name Presbyopia Therapies. The company also announced a new CEO and a fresh start with $47 million in funding to bring its aceclidine eye drop for improving near vision to market with an FDA submission.
Amirah Al Idrus
June 10, 2021
FierceBiotech
Nearly a year after emerging from a Versant Ventures incubator, Bright Peak Therapeutics is reeling in a $107 million series B. The funding will advance Bright Peak's pipeline of cytokine medicines toward the clinic and build out its underlying technology, though the company is keeping details close to the vest.
FinSMEs
June 3, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
Amirah Al Idrus
April 20, 2021
FierceBiotech
Versant Ventures banked $950 million in its latest raise to invest in 20 or more biotech startups and chip into later-stage rounds for its portfolio companies. The capital will be split into three funds, including a primary global fund, a "booster" fund, and a fund for later-stage investments.
Amirah Al Idrus
February 11, 2021
FierceBiotech
Nearly three years after launch, Versant spinout Pipeline Therapeutics is banking $80 million to push its lead neurodegenerative disease programs through the clinic. The funds will bankroll clinical trials for programs in hearing loss and multiple sclerosis while supporting the company's earlier-stage work.
BioSpace
August 5, 2020
BioSpace
Versant Ventures today announced the debut of Matterhorn Biosciences AG, a biotechnology company developing T cell receptor therapies based on the recent discovery of MR1T cells that
July 28, 2020
BioSpace
Versant Ventures Launches Bright Peak Therapeutics - read this article along with other careers information, tips and advice on BioSpace
FinSMEs
June 10, 2020
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.
BioSpace
June 2, 2020
BioSpace
- Combined Company Will Operate as Chinook Therapeutics and Advance Pipeline of Clinical-Stage Programs in Kidney Diseases, Led by Atrasentan and BION-1301 in IgA Nephropathy - Combined Company Will be Well-Funded With Cash Position of ~$200 Million Expected at Closing, Including $25 Million in Additional Investment Committed by Chinook's Existing Investors - Multiple Clinical and Regulatory Pipeline Milestones Planned for Combined Company Over the Next 12-18 Months - Companies to H
Meagan Simpson
August 8, 2019
BetaKit
BlueRock Therapeutics is set to be fully acquired by German multinational pharmaceutical and life sciences company Bayer AG.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.